US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Virtus LifeSci Biotech Clinical Trials ETF

55.15

-0.6100-1.09%

Post-market: 55.150.00000.00%16:10 EDT

Volume:37.34K

Turnover:2.06M

Market Cap:52.39M

PE:- -

High:56.04

Open:56.04

Low:54.67

Close:55.76

52wk High:56.18

52wk Low:22.43

Shares:950.00K

Float Shares:950.00K

Volume Ratio:1.55

T/O Rate:3.93%

Dividend:0.65

Dividend Rate:1.18%

ROE:--

ROA:--

PB:1.18

PE(LYR):- -

Loading ...

Overview Company News Filings

Essential Morning Digest: Key Stories You Shouldn't Miss

Hugging Face CEO Says AI Firms Must Be Held Accountable for Rogue Bot Attacks

MT Newswires Live

Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances

GSK Advances New Toddler Pneumococcal Booster, Signaling Ongoing Vaccine Pipeline Momentum

Moderna Targets Ebola With New mRNA Vaccine Trial: What Investors Should Watch

Biophytis Publishes 2025 Accounts as Trading Resumes Amid Going-Concern Doubts

Grifols says EXCELL Phase 3 trial timeline not ‘new development or a delay’

Zealand Pharma’s New Psoriasis Trial Sets Early Stage for ZP9830

Racura Advances HARNESS-1 Trial After Safe First-Patient Treatment With RC220 Combo

Atea Pharmaceuticals reports C-BEYOND trial meets primary, secondary endpoints

10 Monday AM Reads

The Big Picture

High-Speed Rail Linking Ningbo and Suzhou Reaches New Milestone

White House Correspondents' Dinner Returns Amid Gunfire Shadow, Trump Steals the Spotlight: Considering a Fourth Term Bid

Bristol-Myers Squibb Advances New Lung Cancer Combo Into Phase 2: What Investors Should Watch

Takeda’s Elritercept Trial Targets Anemia in Myelofibrosis, Raising Long-Term Upside for TAK

Jazz Pharmaceuticals Advances Phase 3 Cannabidiol Trial in Severe Childhood Epilepsy

Organon to present results from analysis of Phase 3 trials of VTAMA cream

Kringle Pharma Launches Additional Phase 3 Trial of Oremepermin Alfa in Acute Spinal Cord Injury

MacroGenics Advances MGC026 in Phase 1 Oncology Trial

Verastem doses first patient in TARGET-D 202 Phase 2 trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/BBC/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BBC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBC\",,,,,undefined,":{"symbol":"BBC","market":"US","secType":"STK","nameCN":"Virtus LifeSci Biotech Clinical Trials ETF","latestPrice":55.15,"timestamp":1787774400000,"preClose":55.76,"halted":0,"volume":37342,"hourTrading":{"tag":"盘后","latestPrice":55.15,"preClose":55.15,"latestTime":"16:10 EDT","volume":9,"amount":496.34999999999997,"timestamp":1787775005251,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01093974175035867,"floatShares":950000,"shares":950000,"eps":0,"marketStatus":"Post-Mkt","change":-0.61,"latestTime":"08-26 17:11:25 EDT","open":56.04,"high":56.04,"low":54.665,"amount":2063366,"amplitude":0.024659,"askPrice":62.27,"askSize":100,"bidPrice":27.79,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787788800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":55.76,"sharesOutstanding":900004,"nav":53.969,"aum":51271181.38,"dividendRate":0.01183,"bidAskSpread":0.002083,"postHourTrading":{"tag":"盘后","latestPrice":55.15,"preClose":55.15,"latestTime":"16:10 EDT","volume":9,"amount":496.34999999999997,"timestamp":1787775005251,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.545561,"impliedVol":0.3433,"impliedVolPercentile":0.6414},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBC\",,,,,undefined,":{"symbol":"BBC","floatShares":950000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.545561,"shares":950000,"dividePrice":0.6524,"high":56.04,"amplitude":0.024659,"preClose":55.76,"low":54.665,"week52Low":22.43,"pbRate":"1.18","week52High":56.18,"institutionHeld":0,"latestPrice":55.15,"committee":0.333333,"eps":0,"divideRate":0.01183,"volume":37342,"delay":0,"ttmEps":0,"open":56.04,"prevYearClose":38.56,"prevWeekClose":54.4632,"prevMonthClose":48.7362,"prevQuarterClose":52.6861,"fiveDayClose":56.025,"twentyDayClose":48.4332,"sixtyDayClose":43.8565},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBC\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBC","amount":0.65544,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2024-12-20","symbol":"BBC","amount":0.23947,"announcedDate":"2024-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-20","defaultRemindTime":1734705000000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-20","currency":"USD","dateTimestamp":1734670800000,"payDate":"2024-12-27"},{"date":"2023-12-20","symbol":"BBC","amount":0.0823,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","recordDate":"2023-12-29","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBC\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-29","value":0.0823,"currency":"USD"},{"executeDate":"2024-12-20","recordDate":"2024-12-20","paymentDate":"2024-12-27","value":0.23947,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-29","value":0.65544,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBC\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1163548756","title":"Essential Morning Digest: Key Stories You Shouldn't Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1163548756","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163548756?lang=en_us&edition=fundamental","pubTime":"2026-08-03 07:11","pubTimestamp":1785712273,"startTime":"0","endTime":"0","summary":"Provincial residents looking to start a bed and breakfast or a coffee shop in Guiyang can now benefit from significantly faster approval processes. This summer, the city of \"Cool Guiyang\" is...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656018394","title":"Hugging Face CEO Says AI Firms Must Be Held Accountable for Rogue Bot Attacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2656018394","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656018394?lang=en_us&edition=fundamental","pubTime":"2026-08-01 06:36","pubTimestamp":1785537366,"startTime":"0","endTime":"0","summary":"Hugging Face Chief Executive Clement Delangue said AI developers should be held accountable when their models carry out cyber attacks, BBC reported Friday, after a rogue OpenAI bot breached the company's systems earlier this month.Delangue said Hugging Face rebuilt about a third of its IT network following the incident and would not sue OpenAI, but stressed cyber attacks remain illegal and should not become normalized, BBC reported.Anthropic also disclosed Friday that its Claude chatbot attacked three companies after escaping a testing environment, with the company only discovering the incidents during a review prompted by the OpenAI case, BBC reported.The incidents have sparked debate over who should be held liable when AI agents autonomously carry out cyber attacks after escaping testing sandboxes, BBC reported.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARTY","BBC","QTOC","AGIX","AIPO","VTHR","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655035713","title":"Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2655035713","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655035713?lang=en_us&edition=fundamental","pubTime":"2026-07-31 18:12","pubTimestamp":1785492749,"startTime":"0","endTime":"0","summary":"An update from N4 Pharma ( ($GB:THAT) ) is now available. Thalia Therapeutics plc, an AIM-listed clinical-stage biotech specialising in RNA-based t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/thalia-therapeutics-updates-voting-rights-as-rna-therapy-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/thalia-therapeutics-updates-voting-rights-as-rna-therapy-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BBC","NVIB","BK4585","BK4588","RNA","XBIX","IE0009354923.USD","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655804705","title":"GSK Advances New Toddler Pneumococcal Booster, Signaling Ongoing Vaccine Pipeline Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2655804705","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655804705?lang=en_us&edition=fundamental","pubTime":"2026-07-31 00:32","pubTimestamp":1785429167,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GlaxoSmithKline is running a Phase 1 trial called “A Phase 1, Observer-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-advances-new-toddler-pneumococcal-booster-signaling-ongoing-vaccine-pipeline-momentum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-advances-new-toddler-pneumococcal-booster-signaling-ongoing-vaccine-pipeline-momentum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSKH","BK4007","GSK.UK","BK4532","GSK","BK4585","BK4588","LU1829250122.USD","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655804084","title":"Moderna Targets Ebola With New mRNA Vaccine Trial: What Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2655804084","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655804084?lang=en_us&edition=fundamental","pubTime":"2026-07-31 00:31","pubTimestamp":1785429105,"startTime":"0","endTime":"0","summary":"Moderna ($MRNA) announced an update on their ongoing clinical study. Moderna (MRNA) is launching a Phase 1 trial of its mRNA-1469 vaccine to preven...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/moderna-targets-ebola-with-new-mrna-vaccine-trial-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/moderna-targets-ebola-with-new-mrna-vaccine-trial-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","BK4585","BK4548","MRNY","MRNX","GNOM","ISBC","BBC","BK4211","IDNA","BK4532","WDNA","BK4551","BK4139","LGHT","BK4501","BK4534","MRNA","BK4588","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655801296","title":"Biophytis Publishes 2025 Accounts as Trading Resumes Amid Going-Concern Doubts","url":"https://stock-news.laohu8.com/highlight/detail?id=2655801296","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655801296?lang=en_us&edition=fundamental","pubTime":"2026-07-30 23:59","pubTimestamp":1785427179,"startTime":"0","endTime":"0","summary":"Biophytis ( ($BPTSY) ) has provided an announcement. Biophytis SA, a Paris-based clinical-stage biotechnology group focused on age-related diseases...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biophytis-publishes-2025-accounts-as-trading-resumes-amid-going-concern-doubts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biophytis-publishes-2025-accounts-as-trading-resumes-amid-going-concern-doubts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","BK4588","IEIH","SYNB","JDOC","FWD","BBP","AGNG","DARP","XT","LNGR","RSPH","BBC","FHLC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655890242","title":"Grifols says EXCELL Phase 3 trial timeline not ‘new development or a delay’","url":"https://stock-news.laohu8.com/highlight/detail?id=2655890242","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655890242?lang=en_us&edition=fundamental","pubTime":"2026-07-30 01:55","pubTimestamp":1785347731,"startTime":"0","endTime":"0","summary":"Grifols (GRFS) issued the following statement on the EXCELL Phase 3 trial timeline: “We have noted the recent Bloomberg article referring to the EX...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grifols-says-excell-phase-3-trial-timeline-not-new-development-or-a-delay-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grifols-says-excell-phase-3-trial-timeline-not-new-development-or-a-delay-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GRFS","PSIL","BBC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655897831","title":"Zealand Pharma’s New Psoriasis Trial Sets Early Stage for ZP9830","url":"https://stock-news.laohu8.com/highlight/detail?id=2655897831","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655897831?lang=en_us&edition=fundamental","pubTime":"2026-07-30 00:32","pubTimestamp":1785342730,"startTime":"0","endTime":"0","summary":"Zealand Pharma A/S ($ZLDPF) announced an update on their ongoing clinical study. Zealand Pharma A/S (ZLDPF) has opened a new Phase 1 trial in plaqu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zealand-pharmas-new-psoriasis-trial-sets-early-stage-for-zp9830?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zealand-pharmas-new-psoriasis-trial-sets-early-stage-for-zp9830?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BBC","ZLDPF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655839781","title":"Racura Advances HARNESS-1 Trial After Safe First-Patient Treatment With RC220 Combo","url":"https://stock-news.laohu8.com/highlight/detail?id=2655839781","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655839781?lang=en_us&edition=fundamental","pubTime":"2026-07-29 07:59","pubTimestamp":1785283143,"startTime":"0","endTime":"0","summary":"Race Oncology Ltd. ( ($AU:RAC) ) has shared an announcement. Racura Oncology reported that the first patient in its HARNESS-1 Phase 1 trial has bee...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/racura-advances-harness-1-trial-after-safe-first-patient-treatment-with-rc220-combo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/racura-advances-harness-1-trial-after-safe-first-patient-treatment-with-rc220-combo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654009645","title":"Atea Pharmaceuticals reports C-BEYOND trial meets primary, secondary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2654009645","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654009645?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:21","pubTimestamp":1785237677,"startTime":"0","endTime":"0","summary":"Atea Pharmaceuticals (AVIR) announced topline results from C-BEYOND, its Phase 3 trial conducted in North America evaluating the once-daily fixed-d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atea-pharmaceuticals-reports-c-beyond-trial-meets-primary-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atea-pharmaceuticals-reports-c-beyond-trial-meets-primary-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVIR","PSIL","BK4007","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654045705","title":"10 Monday AM Reads","url":"https://stock-news.laohu8.com/highlight/detail?id=2654045705","media":"The Big Picture","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654045705?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:30","pubTimestamp":1785148206,"startTime":"0","endTime":"0","summary":"What Is Generation Jones And Why It’s Reshaping Succession Planning. Born between 1954 and 1964, now ages 62 to 72, disproportionately represented in CEO and board chair roles over much of the past decade. The term, coined by cultural commentator Jonathan Pontell, refers to a cohort that inherited the cultural promises made to early Boomers but entered adulthood in a more constrained economic era. Almost completely invisible in the generational workforce models guiding your talent strategy. This invisibility isn’t trivia. It’s a structural failure with consequences playing out in every organization right now. . Tesla’s robotaxis are moving in reverse: TechCrunch reports that Tesla’s autonomous driving program is losing ground — regulatory setbacks, safety incidents, and a technology gap that keeps widening as competitors pull ahead.  see also Robotaxis are the new millennial lifestyle subsidy: Sherwood argues the cheap-Uber era is back, with robotaxi VC underwriting the discount this t","market":"us","thumbnail":"https://ritholtz.com/wp-content/uploads/2035/05/cryptohalf.jpg","type":0,"news_type":0,"thumbnails":["https://ritholtz.com/wp-content/uploads/2035/05/cryptohalf.jpg"],"rights":{"source":"ritholtz_highlight","url":"https://ritholtz.com/2026/07/10-monday-am-reads-485/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://ritholtz.com/2026/07/10-monday-am-reads-485/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ritholtz_highlight","symbols":["IE00BZ18W340.USD","BBC","IE00BMQBXF63.USD","AM","IE00BZ18W456.USD","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148750116","title":"High-Speed Rail Linking Ningbo and Suzhou Reaches New Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=1148750116","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148750116?lang=en_us&edition=fundamental","pubTime":"2026-07-27 07:30","pubTimestamp":1785108638,"startTime":"0","endTime":"0","summary":"Ningbo to Suzhou: One-Hour Direct Connection AchievedThe Tongyu High-Speed Railway, a key infrastructure project, has reached a significant construction milestone. On July 26, the critical control...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196237935","title":"White House Correspondents' Dinner Returns Amid Gunfire Shadow, Trump Steals the Spotlight: Considering a Fourth Term Bid","url":"https://stock-news.laohu8.com/highlight/detail?id=1196237935","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196237935?lang=en_us&edition=fundamental","pubTime":"2026-07-25 12:50","pubTimestamp":1784955055,"startTime":"0","endTime":"0","summary":"The White House Correspondents' Dinner resumed on July 24 local time, marking a \"fresh start\" following a shooting incident on April 25.While the organizers aimed to uphold tradition and avoid having...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654036222","title":"Bristol-Myers Squibb Advances New Lung Cancer Combo Into Phase 2: What Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2654036222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654036222?lang=en_us&edition=fundamental","pubTime":"2026-07-25 00:34","pubTimestamp":1784910898,"startTime":"0","endTime":"0","summary":"Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb is running a Phase 2 trial to test a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bristol-myers-squibb-advances-new-lung-cancer-combo-into-phase-2-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bristol-myers-squibb-advances-new-lung-cancer-combo-into-phase-2-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0456855351.SGD","LU1093756168.USD","LU0882574055.USD","LU1868836914.USD","BK4588","LU0061475181.USD","BBC","BK4211","LU1585245621.USD","LU0237698245.USD","IE00BJJMRZ35.SGD","IE00BSNM7G36.USD","LU2242646821.SGD","LU0306807586.USD","LU1983299246.USD","LU0114720955.EUR","BMY","LU1670710588.SGD","LU1868837136.USD","LU1323610961.USD","LU1093756325.SGD","LU0306806265.USD","LU0985481810.HKD","LU2125154778.USD","PSIL","IE00B2B36J28.USD","BK4534","LU1261432733.SGD","LU1868836757.USD","LU0321505868.SGD","ISBC","BK4585","FTXH","LU1670711040.USD","LU0321505439.SGD","LU0225284248.USD","LU1868836591.USD","IHE","LU1074936037.SGD","BK4007","LU0267386448.USD","BK4532","BK4581","LU2125154935.USD","LU0225771236.USD","IE00BFXG1179.USD","IE00BFTCPJ56.SGD","LU1670710661.SGD","LU0432979614.USD","LU1291159041.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654362520","title":"Takeda’s Elritercept Trial Targets Anemia in Myelofibrosis, Raising Long-Term Upside for TAK","url":"https://stock-news.laohu8.com/highlight/detail?id=2654362520","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654362520?lang=en_us&edition=fundamental","pubTime":"2026-07-25 00:34","pubTimestamp":1784910878,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Company ($TAK) announced an update on their ongoing clinical study. Takeda is running a Phase 3 trial to test elritercept (TA...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takedas-elritercept-trial-targets-anemia-in-myelofibrosis-raising-long-term-upside-for-tak?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takedas-elritercept-trial-targets-anemia-in-myelofibrosis-raising-long-term-upside-for-tak?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","TAK","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654036255","title":"Jazz Pharmaceuticals Advances Phase 3 Cannabidiol Trial in Severe Childhood Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2654036255","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654036255?lang=en_us&edition=fundamental","pubTime":"2026-07-25 00:33","pubTimestamp":1784910829,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals ($JAZZ) announced an update on their ongoing clinical study. Jazz Pharmaceuticals is preparing a Phase 3 trial to test a new o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/jazz-pharmaceuticals-advances-phase-3-cannabidiol-trial-in-severe-childhood-epilepsy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/jazz-pharmaceuticals-advances-phase-3-cannabidiol-trial-in-severe-childhood-epilepsy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653204084","title":"Organon to present results from analysis of Phase 3 trials of VTAMA cream","url":"https://stock-news.laohu8.com/highlight/detail?id=2653204084","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653204084?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:11","pubTimestamp":1784895078,"startTime":"0","endTime":"0","summary":"Organon (OGN) will present results from a post hoc analysis of pooled data from the Phase 3 pivotal trials, ADORING 1 and ADORING 2, evaluating the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/organon-to-present-results-from-analysis-of-phase-3-trials-of-vtama-cream-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/organon-to-present-results-from-analysis-of-phase-3-trials-of-vtama-cream-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065171402.SGD","BBC","FXH","BK4588","LU2065171311.SGD","LU2065169927.USD","LU2065170008.USD","OGN","BK4007","BK4559","PSIL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653708145","title":"Kringle Pharma Launches Additional Phase 3 Trial of Oremepermin Alfa in Acute Spinal Cord Injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2653708145","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653708145?lang=en_us&edition=fundamental","pubTime":"2026-07-24 10:52","pubTimestamp":1784861536,"startTime":"0","endTime":"0","summary":"Kringle Pharma, Inc. ( ($JP:4884) ) has shared an announcement. Kringle Pharma has launched an additional Phase 3 trial in Japan to evaluate oremep...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kringle-pharma-launches-additional-phase-3-trial-of-oremepermin-alfa-in-acute-spinal-cord-injury?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kringle-pharma-launches-additional-phase-3-trial-of-oremepermin-alfa-in-acute-spinal-cord-injury?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","PSIL","JP","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653377631","title":"MacroGenics Advances MGC026 in Phase 1 Oncology Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653377631","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653377631?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:33","pubTimestamp":1784838815,"startTime":"0","endTime":"0","summary":"MacroGenics ( ($MGNX) ) just unveiled an update. On July 23, 2026, MacroGenics reported a clinical update from its ongoing Phase 1 trial of MGC026,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/macrogenics-advances-mgc026-in-phase-1-oncology-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/macrogenics-advances-mgc026-in-phase-1-oncology-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653939797","title":"Verastem doses first patient in TARGET-D 202 Phase 2 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653939797","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653939797?lang=en_us&edition=fundamental","pubTime":"2026-07-23 04:06","pubTimestamp":1784750793,"startTime":"0","endTime":"0","summary":"Verastem (VSTM) Oncology announced that the first patient has been dosed in the TARGET-D 202 Phase 2 registration-directed trial evaluating VS-7375...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/verastem-doses-first-patient-in-target-d-202-phase-2-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/verastem-doses-first-patient-in-target-d-202-phase-2-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VSTM","BK4139","BBC","PSIL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":120,"code":"91000000","status":"200"}]}}